Antibody data
- Antibody Data
- Antigen structure
- References [18]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12-9953-41 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- HLA-E Monoclonal Antibody (3D12HLA-E), PE, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The monoclonal antibody 3D12 (HLA-E) recognizes human HLA-E, a member of the Human Leukocyte Antigen family. HLA-E is a MHC Class IB member, which has a specialized role in NK cell recognition. Binding of a restricted set of peptides derived from other Class I leader sequences to the HLA-E and B2M (beta2 microglobulin) complex leads to interaction with NKG2A on NK cells. This binding protects the HLA-G-expressing cell from NK cell killing. HLA-E expression is ubiquitous. Applications Reported: This 3D12 (HLA-E) antibody has been reported for use in flow cytometric analysis. Applications Tested: This 3D12HLA-E antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.5 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Yellow dye
- Isotype
- IgG
- Antibody clone number
- 3D12HLA-E
- Vial size
- 25 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Selection of tumor‑resistant variants following sustained natural killer cell‑mediated immune stress.
Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer.
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis.
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells.
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Human NK cells activated by EBV(+) lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.
Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer.
Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma.
NK cell activation in human hantavirus infection explained by virus-induced IL-15/IL15Rα expression.
The combination of type I IFN, TNF-α, and cell surface receptor engagement with dendritic cells enables NK cells to overcome immune evasion by dengue virus.
Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94.
Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef.
The rapid induction of HLA-E is essential for the survival of antigen-activated naive CD4 T cells from attack by NK cells.
Cutting edge: HLA-E binds a peptide derived from the ATP-binding cassette transporter multidrug resistance-associated protein 7 and inhibits NK cell-mediated lysis.
HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities.
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A.
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A.
Carré T, Thiery J, Janji B, Terry S, Gros G, Meurice G, Kieda C, Olive D, Chouaib S
Oncology reports 2021 Feb;45(2):582-594
Oncology reports 2021 Feb;45(2):582-594
Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer.
Laplagne C, Meddour S, Figarol S, Michelas M, Calvayrac O, Favre G, Laurent C, Fournié JJ, Cabantous S, Poupot M
Frontiers in immunology 2020;11:1396
Frontiers in immunology 2020;11:1396
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.
McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT
Oncoimmunology 2016;5(10):e1226720
Oncoimmunology 2016;5(10):e1226720
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis.
Andersson E, Poschke I, Villabona L, Carlson JW, Lundqvist A, Kiessling R, Seliger B, Masucci GV
Oncoimmunology 2016;5(1):e1052213
Oncoimmunology 2016;5(1):e1052213
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells.
Ruggeri L, Urbani E, André P, Mancusi A, Tosti A, Topini F, Bléry M, Animobono L, Romagné F, Wagtmann N, Velardi A
Haematologica 2016 May;101(5):626-33
Haematologica 2016 May;101(5):626-33
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer A, Wipfler P, Pilz G, Oppermann K, Haschke-Becher E, Afazel S, Kraus J, Trinka E, Sellner J
International journal of molecular sciences 2015 Sep 10;16(9):21832-45
International journal of molecular sciences 2015 Sep 10;16(9):21832-45
Human NK cells activated by EBV(+) lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.
Sánchez-Martínez D, Azaceta G, Muntasell A, Aguiló N, Núñez D, Gálvez EM, Naval J, Anel A, Palomera L, Vilches C, Marzo I, Villalba M, Pardo J
Oncoimmunology 2015 Mar;4(3):e991613
Oncoimmunology 2015 Mar;4(3):e991613
Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer.
Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, Salem N, Walz J, Moretta A, Olive D
Oncotarget 2015 Jun 10;6(16):14360-73
Oncotarget 2015 Jun 10;6(16):14360-73
Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma.
Rygh CB, Wang J, Thuen M, Gras Navarro A, Huuse EM, Thorsen F, Poli A, Zimmer J, Haraldseth O, Lie SA, Enger PØ, Chekenya M
PloS one 2014;9(9):e108414
PloS one 2014;9(9):e108414
NK cell activation in human hantavirus infection explained by virus-induced IL-15/IL15Rα expression.
Braun M, Björkström NK, Gupta S, Sundström K, Ahlm C, Klingström J, Ljunggren HG
PLoS pathogens 2014 Nov;10(11):e1004521
PLoS pathogens 2014 Nov;10(11):e1004521
The combination of type I IFN, TNF-α, and cell surface receptor engagement with dendritic cells enables NK cells to overcome immune evasion by dengue virus.
Lim DS, Yawata N, Selva KJ, Li N, Tsai CY, Yeong LH, Liong KH, Ooi EE, Chong MK, Ng ML, Leo YS, Yawata M, Wong SB
Journal of immunology (Baltimore, Md. : 1950) 2014 Nov 15;193(10):5065-75
Journal of immunology (Baltimore, Md. : 1950) 2014 Nov 15;193(10):5065-75
Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94.
Cheent KS, Jamil KM, Cassidy S, Liu M, Mbiribindi B, Mulder A, Claas FH, Purbhoo MA, Khakoo SI
Proceedings of the National Academy of Sciences of the United States of America 2013 Oct 15;110(42):16981-6
Proceedings of the National Academy of Sciences of the United States of America 2013 Oct 15;110(42):16981-6
Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef.
Sloan RD, Kuhl BD, Donahue DA, Roland A, Bar-Magen T, Wainberg MA
Journal of virology 2011 Mar;85(6):2828-36
Journal of virology 2011 Mar;85(6):2828-36
The rapid induction of HLA-E is essential for the survival of antigen-activated naive CD4 T cells from attack by NK cells.
Takao S, Ishikawa T, Yamashita K, Uchiyama T
Journal of immunology (Baltimore, Md. : 1950) 2010 Nov 15;185(10):6031-40
Journal of immunology (Baltimore, Md. : 1950) 2010 Nov 15;185(10):6031-40
Cutting edge: HLA-E binds a peptide derived from the ATP-binding cassette transporter multidrug resistance-associated protein 7 and inhibits NK cell-mediated lysis.
Wooden SL, Kalb SR, Cotter RJ, Soloski MJ
Journal of immunology (Baltimore, Md. : 1950) 2005 Aug 1;175(3):1383-7
Journal of immunology (Baltimore, Md. : 1950) 2005 Aug 1;175(3):1383-7
HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities.
Strong RK, Holmes MA, Li P, Braun L, Lee N, Geraghty DE
The Journal of biological chemistry 2003 Feb 14;278(7):5082-90
The Journal of biological chemistry 2003 Feb 14;278(7):5082-90
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A.
Lee N, Llano M, Carretero M, Ishitani A, Navarro F, López-Botet M, Geraghty DE
Proceedings of the National Academy of Sciences of the United States of America 1998 Apr 28;95(9):5199-204
Proceedings of the National Academy of Sciences of the United States of America 1998 Apr 28;95(9):5199-204
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A.
Lee N, Llano M, Carretero M, Ishitani A, Navarro F, López-Botet M, Geraghty DE
Proceedings of the National Academy of Sciences of the United States of America 1998 Apr 28;95(9):5199-204
Proceedings of the National Academy of Sciences of the United States of America 1998 Apr 28;95(9):5199-204
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Anti-Human HLA-ABC FITC (Product # 11-9983-42) and Mouse IgG1 kappa Isotype Control PE (Product # 12-4714-81) (left) or Anti-Human HLA-E PE (right). Cells in the lymphocyte gate were used for analysis.
- Conjugate
- Yellow dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Yellow dye